Inflammatory Choroidal Neovascular Membranes: Clinical Profile, Treatment Effectiveness, and Visual Prognosis
Purpose. To characterise a sample of patients with inflammatory choroidal neovascularization (I-CNV), including clinical profile, underlying aetiology and its course, treatments performed, associated clinical response, and visual prognosis. Methods. Retrospective analysis of patients with a diagnosi...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2021/9982883 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560677002149888 |
|---|---|
| author | Gonçalo Carrola Mário Lima-Fontes Fernando Falcão-Reis Luís Figueira Ângela Carneiro |
| author_facet | Gonçalo Carrola Mário Lima-Fontes Fernando Falcão-Reis Luís Figueira Ângela Carneiro |
| author_sort | Gonçalo Carrola |
| collection | DOAJ |
| description | Purpose. To characterise a sample of patients with inflammatory choroidal neovascularization (I-CNV), including clinical profile, underlying aetiology and its course, treatments performed, associated clinical response, and visual prognosis. Methods. Retrospective analysis of patients with a diagnosis of I-CNV followed at the Ophthalmology Department of Centro Hospitalar Universitário de São João (CHUSJ). Clinical and visual outcomes were classified according to the difference in visual acuity after treatment. Results. Twenty eyes from 17 patients were analysed (11 female and 6 male patients, mean age 41.90 ± 16.457 years at CNV diagnosis). Punctate inner choroidopathy/multifocal choroiditis was the predominant inflammatory aetiology (10 patients, 58.82%). Median follow-up time was 46 months (range 10 to 188 months). Neovascularization was treated with intravitreal anti-VEGF injections (bevacizumab, aflibercept, and ranibizumab), and inflammation with anti-inflammatory/immunosuppressive therapy (oral, intravenous, and/or intravitreal corticosteroids; oral cyclosporine or methotrexate). Intravitreal anti-VEGF agents had a median number of 7.00 injections (IQR, 4.25 to 29.00). Visual acuity among 20 eyes had a mean gain of 15.10 ± 12.998 ETDRS letters after anti-VEGF treatment (p=0.000051). According to our classification, 16 had an improved outcome (80.00%), 3 had a stable outcome (15.00%), and 1 had a worsened visual outcome (5.00%). In addition, 13 eyes (65.00%) had a final VA equal to or greater than 65 letters. Recurrence was seen in 3 eyes (15.00%). Complications included cataract (6 patients) and ocular hypertension (4 patients). Conclusion. A combined approach with anti-VEGF agents and anti-inflammatory therapy was effective in I-CNV treatment, and an overall good visual prognosis was attainable. Intensive follow-up was fundamental in the management of both the primary inflammatory and secondary neovascular conditions. |
| format | Article |
| id | doaj-art-86566d33649d41ffa14f4d96be92ff7a |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-86566d33649d41ffa14f4d96be92ff7a2025-02-03T01:27:05ZengWileyJournal of Ophthalmology2090-004X2090-00582021-01-01202110.1155/2021/99828839982883Inflammatory Choroidal Neovascular Membranes: Clinical Profile, Treatment Effectiveness, and Visual PrognosisGonçalo Carrola0Mário Lima-Fontes1Fernando Falcão-Reis2Luís Figueira3Ângela Carneiro4Faculty of Medicine, University of Porto, Porto, PortugalDepartment of Ophthalmology, São João Hospital University Centre, Porto, PortugalDepartment of Ophthalmology, São João Hospital University Centre, Porto, PortugalDepartment of Ophthalmology, São João Hospital University Centre, Porto, PortugalDepartment of Ophthalmology, São João Hospital University Centre, Porto, PortugalPurpose. To characterise a sample of patients with inflammatory choroidal neovascularization (I-CNV), including clinical profile, underlying aetiology and its course, treatments performed, associated clinical response, and visual prognosis. Methods. Retrospective analysis of patients with a diagnosis of I-CNV followed at the Ophthalmology Department of Centro Hospitalar Universitário de São João (CHUSJ). Clinical and visual outcomes were classified according to the difference in visual acuity after treatment. Results. Twenty eyes from 17 patients were analysed (11 female and 6 male patients, mean age 41.90 ± 16.457 years at CNV diagnosis). Punctate inner choroidopathy/multifocal choroiditis was the predominant inflammatory aetiology (10 patients, 58.82%). Median follow-up time was 46 months (range 10 to 188 months). Neovascularization was treated with intravitreal anti-VEGF injections (bevacizumab, aflibercept, and ranibizumab), and inflammation with anti-inflammatory/immunosuppressive therapy (oral, intravenous, and/or intravitreal corticosteroids; oral cyclosporine or methotrexate). Intravitreal anti-VEGF agents had a median number of 7.00 injections (IQR, 4.25 to 29.00). Visual acuity among 20 eyes had a mean gain of 15.10 ± 12.998 ETDRS letters after anti-VEGF treatment (p=0.000051). According to our classification, 16 had an improved outcome (80.00%), 3 had a stable outcome (15.00%), and 1 had a worsened visual outcome (5.00%). In addition, 13 eyes (65.00%) had a final VA equal to or greater than 65 letters. Recurrence was seen in 3 eyes (15.00%). Complications included cataract (6 patients) and ocular hypertension (4 patients). Conclusion. A combined approach with anti-VEGF agents and anti-inflammatory therapy was effective in I-CNV treatment, and an overall good visual prognosis was attainable. Intensive follow-up was fundamental in the management of both the primary inflammatory and secondary neovascular conditions.http://dx.doi.org/10.1155/2021/9982883 |
| spellingShingle | Gonçalo Carrola Mário Lima-Fontes Fernando Falcão-Reis Luís Figueira Ângela Carneiro Inflammatory Choroidal Neovascular Membranes: Clinical Profile, Treatment Effectiveness, and Visual Prognosis Journal of Ophthalmology |
| title | Inflammatory Choroidal Neovascular Membranes: Clinical Profile, Treatment Effectiveness, and Visual Prognosis |
| title_full | Inflammatory Choroidal Neovascular Membranes: Clinical Profile, Treatment Effectiveness, and Visual Prognosis |
| title_fullStr | Inflammatory Choroidal Neovascular Membranes: Clinical Profile, Treatment Effectiveness, and Visual Prognosis |
| title_full_unstemmed | Inflammatory Choroidal Neovascular Membranes: Clinical Profile, Treatment Effectiveness, and Visual Prognosis |
| title_short | Inflammatory Choroidal Neovascular Membranes: Clinical Profile, Treatment Effectiveness, and Visual Prognosis |
| title_sort | inflammatory choroidal neovascular membranes clinical profile treatment effectiveness and visual prognosis |
| url | http://dx.doi.org/10.1155/2021/9982883 |
| work_keys_str_mv | AT goncalocarrola inflammatorychoroidalneovascularmembranesclinicalprofiletreatmenteffectivenessandvisualprognosis AT mariolimafontes inflammatorychoroidalneovascularmembranesclinicalprofiletreatmenteffectivenessandvisualprognosis AT fernandofalcaoreis inflammatorychoroidalneovascularmembranesclinicalprofiletreatmenteffectivenessandvisualprognosis AT luisfigueira inflammatorychoroidalneovascularmembranesclinicalprofiletreatmenteffectivenessandvisualprognosis AT angelacarneiro inflammatorychoroidalneovascularmembranesclinicalprofiletreatmenteffectivenessandvisualprognosis |